To overcome these issues, Rodrik-Outmezguine et colleagues [156] generated the “third generation” mTOR inhibitor, the so called Rapalink, which showed strong anti-tumor activity in breast cancer cells expressing the wild-type allele of mTOR or its resistant forms for both rapalogs and mTORKi. The gene discussed is MTOR; the disease is breast carcinoma.